Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01691079 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes
A Phase 4 study of Bronchospasm, Exercise-Induced, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01691079: Completed Phase 4 study of Bronchospasm, Exercise-Induced, sponsored by University of California, San Francisco.
NCT01691079 is a Phase 4 study of Bronchospasm, Exercise-Induced that has completed, run by University of California, San Francisco. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01691079, a Phase 4 study of Bronchospasm, Exercise-Induced, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a double-blind placebo-controlled study in which we plan to study 40 competitive endurance athletes. We will conduct an exercise test to evaluate maximal oxygen uptake and 2 exercise challenge tests to provoke EIA. Prior to the exercise challenge tests the athletes will randomly receive inhaled placebo or inhaled ipratropium bromide. We will compare the athletes' airway response to the exercise challenge with and without the active drug.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ipratropium bromide
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 4 |
What the finished NCT01691079 record still lists
NCT01691079 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Bronchospasm, Exercise-Induced appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01691079 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01691079 about?
NCT01691079 is a clinical study titled "Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes". This will be a double-blind placebo-controlled study in which we plan to study 40 competitive endurance athletes. We will conduct an exercise test to evaluate maximal oxygen uptake and 2 exercise challenge tests to provoke EIA. Prior to the exercise challenge tests the athletes will randomly receive...
What is the current status of trial NCT01691079?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2012-12. Estimated completion is 2014-12.
What conditions does trial NCT01691079 study?
This clinical trial studies the following conditions: Bronchospasm, Exercise-Induced.
What interventions are being tested in trial NCT01691079?
The interventions under investigation include: Placebo (DRUG), ipratropium bromide (DRUG).
Who is sponsoring clinical trial NCT01691079?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01691079 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01691079's enrollment target sits among peer trials
20 1753rd of 2000 higher than 167 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia